Skip to main content
. Author manuscript; available in PMC: 2013 Dec 9.
Published in final edited form as: Cancer. 2010 Nov 18;117(12):10.1002/cncr.25750. doi: 10.1002/cncr.25750

Figure 1.

Figure 1

These charts illustrate landmark analyses for overall survival according to progression status (A) at 3 months and (B) at 6 months after the initiation of targeted therapy.